Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease

• Main Authors: Qing-Wei Ma (Author), Rui-Ting Han (Author), Zi-Jie Wu (Author), Jun-Jie Zhou (Author), Meng-Ting Chen (Author), Xiang-Zhi Zhang (Author), Wen-Zhe Ma (Author), Na Feng (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Both continuous oxidative stress and poly (ADP-ribose) polymerase 1 (PARP-1) activation occur in neurodegenerative diseases such as Parkinson's disease. PARP-1 inhibition can reverse mitochondrial damage and has a neuroprotective effect. In a previous study, we synthesized melatonin derivative...